China Pharma News Roundup May 11th 2020
Top recent news from Chinese pharma, including listings on the Hong Kong Stock Exchange, Junshi’s out-licensing of a potential COVID-19 treatment to Lilly, and Ascentage being granted US FDA orphan…
Address: 4th Floor, 4/B, 233 Zhen Ning Lu
Rong Xuan Building
200050 – Shanghai / CHINA
Tel: +(86) 151 1797 6292
Web: http://www.acropolis-associates.com/
We assist multinational organizations, small and medium sized enterprises as well as smaller niche companies to attract, recruit and retain outstanding executives and senior managers through our specialist search techniques as well as through our strategic leadership consultancy services.At Acropolis-Associates, our outstanding staff is committed to provide its clients with executives, professionals and specialists whose skills will enhance and improve your business performance and profitability.Acropolis-Associates, professional recruitment consultancy, is committed to deliver the very best talent to its international clients. We operate from offices covering USA, France and China. Our talented professionals pursue the highest level of integrity and quality in providing a clear portfolio of services: executive search, recruitment, placement, and staff integrity.For more than 9 years, Acropolis-Associates has been devoted in delivering its services to organizations by strengthening management teams and their international staff.
» Executive Search
» Recruitment / Placement
» Corporate Fraud Alert (CFA)
» Building an Ethical Framework (BEF)
» Staff & Suppliers Integrity investigation (SSII)
» Education, Study abroad (China – USA / China – Europe)
Top recent news from Chinese pharma, including listings on the Hong Kong Stock Exchange, Junshi’s out-licensing of a potential COVID-19 treatment to Lilly, and Ascentage being granted US FDA orphan…
A selection of recent big stories from Chinese pharma, including Novo Nordisk’s updated China strategy, Chinese biotechs’ funding successes, and some significant regulatory approvals. In Q1 2020, China’s regulator…
I-Mab Biopharma CFO Jielun Zhu recaps the exciting milestones for the company over the past year since our last interview in May 2019, including most notably their NASDAQ IPO in…
PharmaBoardroom caught up with Dr Jingsong Wang, chairman & CEO of Harbour BioMed to discuss the exciting clinical and commercial milestones of the prolific biotech in the last year since…
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) highlights the leaps and bounds with which the Chinese pharmaceutical industry has developed in recent years, the…
Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro diagnostics to brand itself…
Chinese biotech Clover Biopharmaceuticals may have flown under the radar thus far but it has stepped into the global limelight recently by partnering with GSK to develop a vaccine from…
2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been…
Regular PharmaBoardroom contributor David Crean looks at how the ongoing global coronavirus outbreak has impacted the global economy, how the biopharmaceutical industry is responding, and what the longer-term consequences of…
Bing Xu, GM of Vital River Laboratories, shares the company’s development in the last 20 years; the challenges of advantages of their JV with Charles River Laboratories; the importance of…
This new issue of China Healthcare and Life Sciences Review (compiled in December 2019) provides a retrospective of the tremendous gains the Chinese healthcare industry made in 2019 while simultaneously…
Eurasia Group’s Aditya Bhattacharji examines the unfolding coronavirus outbreak, the prospects for China’s political and economic stability, and how healthcare firms should think about the path forward. China appears to…
See our Cookie Privacy Policy Here
